ALDH8A1抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Mouse liver tissue, Mouse kidney tissue, Primary antibody: P07816(ALDH8A1 Antibody) at dilution 1/800, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 3 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P07816(ALDH8A1 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain  tissue using P07816(ALDH8A1 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The ALDH8A1 antibody is a research tool designed to detect aldehyde dehydrogenase family 8 member A1 (ALDH8A1), an enzyme belonging to the ALDH superfamily involved in aldehyde metabolism. ALDH8A1 catalyzes the NAD(P)+-dependent oxidation of retinaldehyde to retinoic acid, a critical signaling molecule in development and cellular differentiation. Unlike other ALDH isoforms, ALDH8A1 exhibits unique substrate specificity and tissue distribution, with higher expression reported in liver, kidney, and brain. Its role extends beyond retinoid metabolism, potentially influencing neurotransmitter metabolism (e.g., dopamine degradation) and cellular detoxification pathways.

Antibodies against ALDH8A1 are primarily used in basic research to investigate its expression patterns, subcellular localization (predominantly cytosolic), and regulatory mechanisms under physiological or pathological conditions. They enable detection via Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Commercial ALDH8A1 antibodies are typically raised in rabbits or mice using peptide immunogens corresponding to specific epitopes, with validation in knockdown cell lines or ALDH8A1-deficient models to confirm specificity.

Current studies employ these antibodies to explore ALDH8A1's involvement in diseases such as cancer (e.g., hepatocellular carcinoma progression), neurological disorders, and metabolic syndromes. Researchers should verify antibody performance across experimental models due to potential cross-reactivity with ALDH isoforms or species-specific epitope variations. Proper controls and validation remain essential, as ALDH8A1 exists in multiple splice variants with unclear functional distinctions.